Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple MyelomaSundar Jagannath, Peter M. Voorhees, Myo Htut et al.|Journal of Clinical Oncology|2025Cited by 107
Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 TrialM Hasib Sidiqi, Kwee Yong, Paolo Corradini et al.|Blood|2023Cited by 4
Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma and 1–3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 Cartitude-4 TrialM Hasib Sidiqi, Kwee Yong, Paolo Corradini et al.|Transplantation and Cellular Therapy|2024Cited by 1
Biomarker Correlates of 3 Year Response in Cartitude-1: A Phase 1b/2 Open-Label Study of Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple MyelomaYi Lin, Rui Wang, Saad Z. Usmani et al.|Transplantation and Cellular Therapy|2024Cited by 1
E-260 Bilateral cerebral arteriovenous shunting through pial and perforating vessels with multiple strokes and intraparenchymal hemorrhages in a patient with hepatopulmonary syndromeBaha’ Aljeradat, H Shaikh, Mythili Koneru et al.|Unknown|2023Cited by 0